March 17 (Reuters) - Molecular testing firm Qiagen NV QIA.DE stated on Tuesday it will ramp up its
March 17 (Reuters) – Molecular testing firm Qiagen NV QIA.DE stated on Tuesday it will ramp up its international capability to supply sure chemical kits used to check COVID-19, aiming to assist greater than 6.5 million assessments a month by April finish.
The German firm, which is being purchased by Thermo Fisher Scientific TMO.N in an $11.5 billion deal, provides RNA extraction kits used to arrange affected person samples for some coronavirus assessments.
The kits are used to extract a form of genetic materials referred to as RNA from affected person blood or tissue samples, in order that any virus may be recognized. They don’t seem to be particular to the coronavirus, however are used for routine assessments equivalent to HIV.
The corporate stated it goals to assist over 10 million assessments by June finish, up from its historic manufacturing capability that helps about 1.5 million assessments a month.
Plans are beneath approach at its websites in Europe and the US to succeed in greater than 20 million affected person assessments a month by the tip of the yr, the corporate stated.
…